Phase 2a study of CM-101, a CCL24 neutralizing antibody, in patients with non-alcoholic steatohepatitis: a proof-of-concept study

Authors:
  • RSRifaat Safadi
    Rifaat Safadi
  • JLJohn Lawler
    John Lawler
  • RARevital Aricha
    Revital Aricha
  • IVIlan Vaknin
    Ilan Vaknin
  • SFScott Friedman
    Scott Friedman
  • AMAdi Mor
    Adi Mor

Abstract
No abstract available